TY - JOUR
T1 - Understanding and retention of trial-related information among participants in a clinical trial after completing the informed consent process
AU - Mexas, Fernanda
AU - Efron, Anne
AU - Luiz, Ronir Raggio
AU - Cailleaux-Cezar, Michelle
AU - Chaisson, Richard E.
AU - Conde, Marcus B.
N1 - Funding Information:
Fernanda Mexas was supported by a grant (process #135564/2011-5) from the National Council for Scientific and Technological Development (CNPq). Marcus B. Conde has a grant from CNPq (300414/2010-2) and from Fundacao de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ; E26/101491/2010). The RioMAR study is supported by grant 5U19AI045432 from the National Institute of Allergy and Infectious Diseases and contract 200-2009-32587 from the Centers for Disease Control and Prevention.
PY - 2014/2
Y1 - 2014/2
N2 - Background Methods for assessing the level of understanding of trial-related information during the informed consent (IC) process in developing countries are lacking. Purpose To assess the understanding and retention of trial-related information presented in the IC process by administering an informed consent assessment instrument (ICAI) to participants in a clinical trial for a new tuberculosis (TB) regimen being conducted in Rio de Janeiro (Brazil). Methods The format of the ICAI was based on the language and structure of the United States National Cancer Institute's IC comprehension checklist. The ICAI was designed to assess points of the RioMAR study IC process that addressed the principles of research ethics requested by Brazilian Regulatory Authority: autonomy, beneficence, non-maleficence, and justice. Briefly, (1) Is the respondent participating in a clinical trial? (2) Are two different treatments being evaluated? (3) Is the treatment arm chosen by chance? (4) Is an HIV test required? (5) Are liver function tests required? (6) Can participants leave the study at any time? (7) Are the risks and benefits of taking part in the study clear? (8) May pregnant women participate in the study? (9) Can one of the study drugs reduce the effectiveness of contraceptives? (10) Are patients paid to participate in the study? The ICAI was applied at two time points: immediately after enrollment in the clinical trial and 2 months later. Results A total of 61 patients who enrolled in the RioMAR study participated in this study. The percentage of correct answers to all questions was 82% at the time of the first ICAI; 31 participants (51%) did not recall that an HIV test was required (question 4) and 43 (70%) did not know that they could leave the study (question 6). Other individual questions were answered correctly by at least 76% of participants. There was no association between incorrect answers and age, gender, monthly family income, neighborhood, or level of education (p > 0.07). When the responses to the first and the second ICAI questions were compared, 15% or more of participants had conflicting answers to 5 of the 10 questions. Limitations The ICAI uses dichotomous responses, leading to a 50% chance of guessing the correct answers. Two questions were asked only of women. Finally, only 6 of the 10 questions on the current version of the ICAI apply to most trials; others are trial-specific.
AB - Background Methods for assessing the level of understanding of trial-related information during the informed consent (IC) process in developing countries are lacking. Purpose To assess the understanding and retention of trial-related information presented in the IC process by administering an informed consent assessment instrument (ICAI) to participants in a clinical trial for a new tuberculosis (TB) regimen being conducted in Rio de Janeiro (Brazil). Methods The format of the ICAI was based on the language and structure of the United States National Cancer Institute's IC comprehension checklist. The ICAI was designed to assess points of the RioMAR study IC process that addressed the principles of research ethics requested by Brazilian Regulatory Authority: autonomy, beneficence, non-maleficence, and justice. Briefly, (1) Is the respondent participating in a clinical trial? (2) Are two different treatments being evaluated? (3) Is the treatment arm chosen by chance? (4) Is an HIV test required? (5) Are liver function tests required? (6) Can participants leave the study at any time? (7) Are the risks and benefits of taking part in the study clear? (8) May pregnant women participate in the study? (9) Can one of the study drugs reduce the effectiveness of contraceptives? (10) Are patients paid to participate in the study? The ICAI was applied at two time points: immediately after enrollment in the clinical trial and 2 months later. Results A total of 61 patients who enrolled in the RioMAR study participated in this study. The percentage of correct answers to all questions was 82% at the time of the first ICAI; 31 participants (51%) did not recall that an HIV test was required (question 4) and 43 (70%) did not know that they could leave the study (question 6). Other individual questions were answered correctly by at least 76% of participants. There was no association between incorrect answers and age, gender, monthly family income, neighborhood, or level of education (p > 0.07). When the responses to the first and the second ICAI questions were compared, 15% or more of participants had conflicting answers to 5 of the 10 questions. Limitations The ICAI uses dichotomous responses, leading to a 50% chance of guessing the correct answers. Two questions were asked only of women. Finally, only 6 of the 10 questions on the current version of the ICAI apply to most trials; others are trial-specific.
UR - http://www.scopus.com/inward/record.url?scp=84893899845&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84893899845&partnerID=8YFLogxK
U2 - 10.1177/1740774513509316
DO - 10.1177/1740774513509316
M3 - Article
C2 - 24296322
AN - SCOPUS:84893899845
SN - 1740-7745
VL - 11
SP - 70
EP - 76
JO - Clinical Trials
JF - Clinical Trials
IS - 1
ER -